Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7653671 | 0.89 | — | — | |
| SCHEMBL8664168 | 0.81 | — | — | |
| SCHEMBL8865443 | 0.79 | RARA (0.37) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL8661225 | 0.75 | ALDH1A1 (0.33) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL8658232 | 0.73 | CYP3A4 (0.41) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL8865522 | 0.73 | CYP3A4 (0.33) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL8663165 | 0.72 | CYP3A4 (0.37) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL8865791 | 0.71 | RARA (0.37) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL8865035 | 0.71 | CYP3A4 (0.34) | CYP3A4RARARARBRARGKMT2A | |
| SCHEMBL7659021 | 0.70 | CYP3A4 (0.38) | CYP3A4RARARARBRARGKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5750693-A | THIOCHROMANYL OR CHROMANYL COMPOUNDS AS ANTICARCINOGINIC AGENTS, SKIN DISORDERS AND ATHEROSCLEROSIS | ALLERGAN (US) | 1998-05-12 | — | — | US | disclosed |
| US-5677451-A | CONTROLLING CELL DIFFERENTIATION; SKIN DISORDERS; ANTICANCER AGENTS | ALLERGAN (US) | 1997-10-14 | — | — | US | disclosed |